ACIP Changes Disrupt Vaccine Coverage Pipeline, Raise Cost Concerns

For decades, the CDC Advisory Committee on Immunization Practices (ACIP) served as the linchpin of pediatric vaccine policy, and by extension, the basis on which insurers determined what they would cover. When ACIP recommended a vaccine, coverage followed. That equation is now broken, and the financial fallout will be felt most acutely by families least equipped to absorb it, according to a panel of experts.

The 2026 ACIP changes removed routine recommendations for the hepatitis B birth dose, nirsevimab (Beyfortus) for RSV prevention in infants, and several adolescent vaccines, while reclassifying others as requiring shared clinical decision-making.^1,2 For payers, health systems, and the underserved populations they serve, the ripple effects are only beginning.

To address the continued changes and associated confusion, The American Journal of Managed Care^® and its sister publications Contagion^®, Pharmacy Times^®, Contemporary Pediatrics^®, HCPLive^®, and Contemporary OB/GYN^® called upon several experts to join the “Clinical Insights: Childhood Vaccine Schedule Changes” roundtable and break down the recent changes to the federal vaccine schedule. John Parkinson, assistant managing editor of Contagion, moderated this discussion.

The Coverage Mechanism and Why It's Now in Jeopardy

Private insurers have historically tied pediatric vaccine coverage directly to ACIP recommendations. Under the Affordable Care Act, vaccines with an ACIP "A" or "B" rating must be covered without cost-sharing.³ Remove the recommendation, and the legal obligation to cover disappears with it.

For now, payers appear to be holding steady. "The insurance industry has continued to fund the vaccines," William Schaffner, MD, professor of preventive medicine and infectious diseases at Vanderbilt University Medical Center. "They recognize that there is this turmoil out there, and they're still focused on the recommendations made by the previous ACIP."

But that stability may be short-lived. "A year from now, I think that's going to be quite different," said Sharon Nachman, MD, division chief for pediatric infectious disease at Stony Brook Children's Hospital. "The cost of these vaccines is going to be enormous. Some of them are $200, $300 a pop. You need a couple of vaccines each time you come in,” she explained. “As they age, you have more than one kid. That bill just goes up and up."

A Federal Safety Net Under Strain

Compounding the private insurance concern is mounting uncertainty around the Vaccines for Children (VFC) program, which provides free vaccines to uninsured, Medicaid-enrolled, and underserved children.³ VFC coverage is keyed to ACIP recommendations, meaning that vaccines removed from or downgraded in the ACIP schedule may no longer qualify for federal funding.^4,5

"We are concerned that some federal funding under the Vaccines for Children program, perhaps going into the future, may be in peril," Schaffner said. "We'll just have to see how that goes."

For pediatric providers serving low-income populations, VFC is often the only mechanism ensuring a child receives any vaccine at all. "The underserved children are probably going to be the worst off, because who's going to pay for them?" Mary Koslap-Petraco, DNP, PNP-BC, CPNP, a pediatric nurse practitioner, clinical assistant professor at Stony Brook University School of Nursing, and former immunization program director at Suffolk County Department of Health Services, said. "My big fear is, what happens to the underserved children who don't have a grandma like me or like Dr Nachman, who can stick our hand in our pocket and say we're going to pay for those vaccines?"

That fear is not hypothetical. Both Koslap-Petraco and Jacinda Abdul-Mutakabbir, PharmD, MPH, assistant professor of clinical pharmacy and antimicrobial resistance researcher at UC San Diego, disclosed that they personally purchase vaccines out of pocket to distribute in the communities they serve. "I budget for that to make sure that we can provide at least some vaccines to some families that are in need," she said. It is a workaround that speaks to provider desperation, and one that is plainly not scalable as policy.

The Payer Arbitrage Problem

Reclassifying vaccines as shared clinical decision-making creates an additional financial risk. If ACIP no longer unambiguously recommends a vaccine, insurers can reasonably argue they are not obligated to cover it under the Affordable Care Act’s preventive care provisions.³

Abdul-Mutakabbir raised this concern directly: "It makes it a little bit easier for them to say, 'Hey, we're going to follow ACIP. ACIP doesn't recommend this. Now we don't want to pay for this vaccine anymore.' So that's definitely something for us to think about."

Provider liability is a related concern. "Folks may feel like they could be sued in the event that they were to give a vaccine that may not be ACIP-recommended," Abdul-Mutakabbir explained, "or that maybe they are more liable for reporting when it comes to vaccine injury, if it's a vaccine that is not recommended by ACIP." The practical result may be a chilling effect, with providers declining to recommend vaccines that are neither clearly covered nor clearly protected.

Costs That Won't Surface for Decades

For managed care organizations focused on near-term utilization, the full cost of reduced vaccine uptake will not appear in quarterly reports. Hepatitis B is the clearest example. Removing the birth-dose recommendation will not register in claims data for years.

"Hepatitis B is a decades-long problem," Nachman warned. "Two decades from now, we're going to see hepatitis C, cirrhosis, liver cancers. And at that point, no one's going to remember who in the world said don't give kids hepatitis B vaccine. But by then it's going to be too late."

A November 2025 preprint modeled exactly this scenario.⁶ A Markov model evaluating health and economic outcomes for infants born in 2024 found that for a single year of delaying the hepatitis B birth dose to just 2 months, an estimated 304 additional liver cancer cases and 482 HBV-related deaths would result, along with over $222 million in excess health care costs. Crucially, those costs accumulate over a lifetime, not in the year of birth.

Koslap-Petraco drew on personal history to underscore the point. "I have very vivid memories of being 7 years old and having one of my aunts tell me a 4-year-old cousin died from hepatitis." Facing the prospect of rolling back a program that has driven hepatitis B to historic lows, she asked: "Do we really want to go back to that?"

The meningitis reclassification raises a similar deferred-cost concern for payers covering college-age populations. "Good news, stopping the meningitis vaccine—you take care of the college kids, it's going to come to your college," Nachman told the roundtable. For Medicaid managed care plans and student health programs, that is a pointed financial forecast.

What Health Systems Can Do Now

The experts pointed to institutional models that have maintained high vaccination rates regardless of policy turbulence. Abdul-Mutakabbir cited a 2026 multihospital study in Washington, DC, showing that some safety-net hospitals, including Howard University, reduced hepatitis B vaccine refusal rates to 0% through coordinated, multidisciplinary prenatal education.⁷

The key, she said, was integrating vaccine education across every discipline, with physicians, pharmacists, and nurses all holding defined roles in counseling expectant mothers.⁸ "They had a workflow, but they had every single part, every single discipline involved," she noted.

Koslap-Petraco described a parallel result in Suffolk County, where a coordinated prenatal education program eliminated hepatitis B refusals across the county health system entirely. Both examples point toward institutional investment in education infrastructure as a more durable solution than relying on individual clinicians to carry the burden alone.

“What kind of car do you have?” Nachman asked. “What happens when it starts making that funky noise? Do you bring it to the mechanic down the block, or do you bring it to the mechanic of the manufacturer? Pediatricians are the same way. We are the experts in your child, and that’s why we are recommending these vaccines to be used.”

Schaffner emphasized that attention should focus on the recommendations from professional societies to address the “noise” from ACIP. “It gives me great sadness to say that. I've been associated in one way or another with the ACIP for many, many years, and to see this wonderful organization now brought down because its recommendations no longer come from science, I think, is very, very sad,” he explained. “My bottom line always is: disease, bad; vaccines, good.”

The Road Ahead

The 2026 ACIP changes have effectively decoupled vaccine policy from the scientific infrastructure that made it credible, and from the coverage machinery that made it accessible. The consequences will not arrive all at once, the experts warned. Rotavirus will resurge in the spring. Meningitis will return to college campuses within years. Hepatitis B's toll will emerge over decades. At each inflection point, the question of who pays will become harder to avoid.

For managed care organizations and health systems, the window to build countervailing infrastructure is open now, before disease burden materializes. The roundtable experts, seasoned enough to remember the diseases vaccines eliminated, were unified in their urgency.

"This is just another challenge that we as health care professionals are well poised to meet," Abdul-Mutakabbir said.

References

1. Grossi G. CDC reduces US childhood immunization schedule from 17 to 11 diseases. AJMC^®. January 5, 2026. Accessed April 6, 2026. https://www.ajmc.com/view/cdc-reduces-us-childhood-immunization-schedule-from-17-to-11-diseases
2. Steinzor P. CDC vaccine rollback highlights gaps in public understanding of shared decision-making. AJMC. January 7, 2026. Accessed April 6, 2026. https://www.ajmc.com/view/cdc-vaccine-rollback-highlights-gaps-in-public-understanding-of-shared-decision-making
3. Kates J. ACIP, CDC, and insurance coverage of vaccines in the United States. KFF. Published June 13, 2025. Accessed April 6, 2026. https://www.kff.org/other-health/acip-cdc-and-insurance-coverage-of-vaccines-in-the-united-states/
4. Congressional Research Service. The Advisory Committee on Immunization Practices (ACIP). CRS InFocus IF12317. Updated September 15, 2025. Accessed April 6, 2026. https://www.congress.gov/crs-product/IF12317
5. Vaccines for Children (VFC) program: information for parents. CDC. Updated September 30, 2025. Accessed April 6, 2026. https://www.cdc.gov/vaccines-for-children/vfc-information-for-parents/
6. Tran TT, Li Y, Lin W, et al. Economic evaluation of delaying the infant hepatitis B vaccination schedule. medRxiv. Published November 24, 2025. doi:10.1101/2025.11.24.25340907
7. Leslie TF, Delamater PL, Abutaleb AO, Yang YT. Institutional drivers of newborn hepatitis B vaccine disparities: a multi-hospital analysis in Washington, DC, 2017–2023. Hum Vaccin Immunother. 2026. doi:10.1080/21645515.2026.2616952
8. Grossi G, Parkinson J, Abdul-Mutakabbir J, et al. Why safety-net hospitals are leading the way on childhood vaccine uptake. AJMC. March 17, 2026. Accessed April 6, 2026. https://www.ajmc.com/view/why-safety-net-hospitals-are-leading-the-way-on-childhood-vaccine-uptake